Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IGHV mutational status and BCR stereotypy in chronic lymphocytic leukemia: A Turkish cohort analysis. | Ann Hematol | 2026 | 42230397 | PubTator, text mining | PubMed |
| Continuous DNA methylation deconvolution-based surrogate for B-cell differentiation state in chronic lymphocytic leukemia. | Commun Med (Lond) | 2026 | 42174048 | PubTator, text mining | PubMed |
| [Long-term outcomes of first-line iFCR regimen in chronic lymphocytic leukemia/small lymphocytic lymphoma and the role of MRD]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | 42161660 | PubTator, text mining | PubMed |
| Entrenchment of germline amino-acid differences in antibody affinity maturation. | bioRxiv | 2026 | 42079148 | PubTator, text mining | PubMed |
| Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study. | Cancer | 2026 | 41983763 | PubTator, text mining | PubMed |
| First-Line Treatment of IGHV-Unmutated Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Targeted and Chemoimmunotherapy Regimens. | Eur J Haematol | 2026 | 41981887 | PubTator, text mining | PubMed |
| Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks. | Eur J Haematol | 2026 | 41974594 | PubTator, text mining | PubMed |
| Outcomes of patients with CLL and borderline IGHV mutational status: a systematic review and meta analysis. | Biomark Res | 2026 | 41964073 | PubTator, text mining | PubMed |
| Prevalence and Impact of Cardiovascular Comorbidities on Disease Outcomes in a Middle Eastern Chronic Lymphocytic Leukemia Population: A Retrospective Study at Kuwait Cancer Control Center. | Med Princ Pract | 2026 | 41926535 | PubTator, text mining | PubMed |
| A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation. | Blood Adv | 2026 | 41886642 | PubTator, text mining | PubMed |
| Porcine influenza mAbs to H3, H5, and H7 hemagglutinins recognize H3 egg adapted site and target the HA stem. | Discov Immunol | 2026 | 41873331 | PubTator, text mining | PubMed |
| Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study. | JCO Clin Cancer Inform | 2026 | 41849725 | PubTator, text mining | PubMed |
| Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective. | Blood Adv | 2026 | 41843779 | PubTator, text mining | PubMed |
| [CAR-T cell therapy bridging to allogeneic hematopoietic stem cell transplantation for diffuse large B-cell Richter syndrome: a case report and literature review]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | 41839634 | PubTator, text mining | PubMed |
| High-risk molecular features may eclipse genomic complexity in predicting chronic lymphocytic leukemia outcomes; UK clinical trial insights. | Leukemia | 2026 | 41814015 | PubTator, text mining | PubMed |
| Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint. | Oncol Res | 2026 | 41799526 | PubTator, text mining | PubMed |
| A single-center retrospective study suggests a potential benefit of BTK inhibitor-based therapy in patients with histologic transformation of Waldenström macroglobulinemia. | Ann Med | 2026 | 41797694 | PubTator, text mining | PubMed |
| Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. | Clin Transl Med | 2026 | 41793184 | PubTator, text mining | PubMed |
| Understanding hairy cell leukemia in the context of mature B-cell neoplasms: tumor microenvironment and extracellular vesicle contribution to disease pathogenesis. | Front Immunol | 2026 | 41789071 | PubTator, text mining | PubMed |
| Proteogenomic features define subtypes of mantle cell lymphoma. | Blood Adv | 2026 | 41785305 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=2